All articles by lroy


Biogen and Amicus win UK Prix Galien awards for rare disease medicines

Biotechnology companies Biogen and Amicus have won the two top prizes for their rare disease medicines at the UK Prix Galien 2018 award ceremony held at London’s House of Commons.

US FDA grants ODD to Lynparza for treatment of pancreatic cancer

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Lynparza (olaparib) to be used for the treatment of pancreatic cancer.

Rival companies to tap $20bn global market with biosimilars for Humira

Rival companies have lined up create biosimilars for Humria (adalimumab), which is currently marketed by US-based biopharmaceutical company AbbVie, as the European patent on the drug is expected to expire tomorrow, reports Financial Times.

FDA panel endorses Celltrion’s biosimilar to Rituxan

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has recommended approval of Celltrion’s Rituxan biosimilar CT-P10.

UK legalises medical cannabis products for prescribed treatment

The UK Government has made medical cannabis legal for the first time in the country for the treatment of patients with related clinical need.

Janssen submits MAA to EMA for esketamine nasal spray

Johnson & Johnson’s Janssen Pharmaceutical Companies has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for its esketamine nasal spray.

ABPI signs five-year collaborative agreement with AHSN

The Association of the British Pharmaceutical Industry (ABPI) has entered into a new partnership with the Academic Health Science Network (AHSN) to support biomedical innovations for the National Health Service (NHS).

Bluebird Bio and Gritstone Oncology partner on cancer cell therapies

US-based biotechnology companies bluebird bio and Gritstone Oncology have entered into strategic collaboration for the development of new cancer cell therapies.

EMA accepts marketing application for trastuzumab and pegfilgrastim

The European Medicines Agency (EMA) has accepted to review Mylan’s marketing authorisation applications (MAA) for proposed biosimilar trastuzumab and proposed biosimilar pegfilgrastim.

Astellas acquires drug discovery subsidiary Mitobridge

Japanese firm Astellas Pharma has exercised its exclusive option right to acquire US-based biotechnology company Mitobridge to accelerate the discovery and development of new treatments that target mitochondrial functions.